Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Summary

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Timeline

Start

2026-06

Primary completion

2028-04

Completion

2028-10

Drugs

Indications